Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald L Lamm

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Current Treatment Options in Oncology|August 27, 2002
Superficial bladder cancerDonald L Lamm
Thescientificworldjournal|September 7, 2004
Superficial bladder cancer therapyEmmanuel Schenkman, Donald L Lamm
Vaccine|August 21, 2021
A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatmentDonald L Lamm, Alvaro Morales
Urology|March 19, 2004
Antitumor activity of common antibiotics against superficial bladder cancerAshish M Kamat, Donald L Lamm
The Urologic Clinics of North America|July 12, 2002
Chemoprevention of bladder cancerAshish M Kamat, Donald L Lamm
BJU International|March 23, 2013
Bacillus Calmette-Guérin immunotherapy for genitourinary cancerNilay M Gandhi, Alvaro Morales, Donald L Lamm
Urologic Nursing|November 22, 2005
Bladder cancer: current optimal intravesical treatmentDonald L Lamm, William R McGee, Kaye Hale
The Canadian Journal of Urology|June 23, 2010
Tumor implantation: a rare but potentially preventable cause of death in cystectomy patientsKevin J Via, Kitty M Burns, Donald L Lamm
The Journal of Urology|October 24, 2002
Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trialsRichard J Sylvester, Adrian P M van der MEIJDEN, Donald L Lamm
The Journal of Urology|September 18, 2010
Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancerKenneth G Nepple, Andrew J Lightfoot, Henry M Rosevear, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Current Treatment Options in Oncology|August 27, 2002
Superficial bladder cancerDonald L Lamm
Thescientificworldjournal|September 7, 2004
Superficial bladder cancer therapyEmmanuel Schenkman, Donald L Lamm
Vaccine|August 21, 2021
A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatmentDonald L Lamm, Alvaro Morales
Urology|March 19, 2004
Antitumor activity of common antibiotics against superficial bladder cancerAshish M Kamat, Donald L Lamm
The Urologic Clinics of North America|July 12, 2002
Chemoprevention of bladder cancerAshish M Kamat, Donald L Lamm
BJU International|March 23, 2013
Bacillus Calmette-Guérin immunotherapy for genitourinary cancerNilay M Gandhi, Alvaro Morales, Donald L Lamm
Urologic Nursing|November 22, 2005
Bladder cancer: current optimal intravesical treatmentDonald L Lamm, William R McGee, Kaye Hale
The Canadian Journal of Urology|June 23, 2010
Tumor implantation: a rare but potentially preventable cause of death in cystectomy patientsKevin J Via, Kitty M Burns, Donald L Lamm
The Journal of Urology|October 24, 2002
Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trialsRichard J Sylvester, Adrian P M van der MEIJDEN, Donald L Lamm
The Journal of Urology|September 18, 2010
Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancerKenneth G Nepple, Andrew J Lightfoot, Henry M Rosevear, et al.
Pageof 3